Comprehensive Hereditary Panels-Hereditary Breast and Ovarian Cancer
Unique Identifier:
ML-N003
Name on Requisition:
Comprehensive Hereditary Panels-Hereditary Breast and Ovarian Cancer
Product Line:
NH
Panel Group:
Hereditary Cancer Panels
Panel Name:
Comprehensive Hereditary Panels-Hereditary Breast and Ovarian Cancer
Methodology
Molecular
NGS
Test Description and clinical significance
Genes
ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, MRE11A, MUTYH, NBN, NF1, PALB2, PTEN, RAD50, RAD51C, RAD51D, STK11, TP53
Disease:
Breast and Ovarian Cancer
The Hereditary Breast and Ovarian Cancer Panel assesses germline variants across multiple genes, including BRCA1, BRCA2, PALB2, CHEK2, ATM, and others, implicated in hereditary breast and ovarian cancer syndromes. This comprehensive panel provides risk assessment, diagnostic insight, and guidance for targeted prevention and management, including screening and therapeutic decision-making.
Specimen Requirements
Preparation:
PB, saliva
Collection:
Specimen should contain least 0.5 mL of peripheral blood (lower volumes may be accepted if situation demands), but we prefer larger specimens in case of a low content of nucleated cells. For saliva, it is recommended to request 1.5-2.0 ml of saliva to be collected from each patient.
Stability:
4 to 7 days refrigerated fpr PB and upto 1 year for slaiva at room temperature
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative or anticoagulant. Specimen received after the stability date. Gross hemolysis. Frozen specimen. Insufficient specimen. Unlabeled. Left un-refrigerated for an extended period.
Storage & Transport
4 to 7 days refrigerated fpr PB and upto 1 year for slaiva at room temperature
CPT(s)
81432
New York Approved
Yes
TAT
14-21
Requisition Type
NH
Levels of Service
Full
DexS Code
Z03NW
Prefix
MI
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
